^
Association details:
| Biomarker: | MCL1 overexpression + HER-2 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | S63845 (MCL1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Excerpt:
We tested the MCL-1 inhibitor S63845 in breast cancer cell lines and patient-derived xenografts with high expression of MCL-1. S63845 displayed synergistic activity with docetaxel in triple-negative breast cancer and with trastuzumab or lapatinib in HER2-amplified breast cancer....Here, we identify MCL-1 as an important target in TNBC and HER2-amplified breast cancer and further demonstrate that S63845 is an on-target MCL-1 inhibitor with promising activity using PDX models.
Secondary therapy:
docetaxel
DOI:
10.1126/scitranslmed.aam7049
